Previously, we demonstrated that 300 nM tipifarnib, which is an FTI, reduces HIF-1α expression in triple-negative breast cancer cells and suppresses migration, cancer stemness, and epithelial-to-mesenchymal transition regardless of RAS expression [31]. Here, HIF1A is linked to cancer.